Drug intelligence / Profile preview

dAMD-2

Development stage: Preclinical
Lead developer: insitro

Overview

dAMD-2 is a preclinical drug candidate developed by insitro for the treatment of dry age-related macular degeneration (dAMD). It was identified through insitro's proprietary machine learning-driven platform, which utilizes high-content phenotypic data and human genetics to discover novel therapeutic targets and candidates. While specific details regarding its molecular target and modality have not been publicly disclosed, the program is part of insitro's ophthalmology pipeline aimed at addressing the underlying biological drivers of retinal degeneration.

Beyond the preview

Go deeper on dAMD-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dAMD-2.

Explore the full profile